Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 2, pp. 300-308
Closed Access | Times Cited: 9

Showing 9 citing articles:

New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 978-981
Closed Access | Times Cited: 2
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 774-779
Open Access | Times Cited: 2
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients
Renata Mangione, Cesarina Giallongo, Andrea Duminuco, et al.
Antioxidants (2024) Vol. 13, Iss. 4, pp. 490-490
Open Access | Times Cited: 2
Treatment‐associated decline inJAK2V617F allele burden in polycythemia vera: What does it mean?
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1459-1461
Closed Access | Times Cited: 2
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
Daniele Cattaneo, Nicole Galli, Cristina Bucelli, et al.
Annals of Hematology (2024)
Closed Access | Times Cited: 2
Hydroxyurea: An Old Drug in Need of New Clinical Trials in Myeloproliferative Neoplasms
A. Manoharan, Sonia I Enggist
(2024)
Open Access | Times Cited: 1
Risk models in myelofibrosis—the past, present, and future
Ayalew Tefferi, Alessandro M. Vannucchi
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 519-522
Closed Access
Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology
Edoardo Peroni, Elisabetta Calistri, Rosario Amato, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access
Peri‐Transplant Management of JAK Inhibitor Therapy in Myelofibrosis
Ayalew Tefferi, Vincent T. Ho
American Journal of Hematology (2024)
Open Access
Page 1

Scroll to top